| Schedule of Segment Information |
The following table provides information about the Company's single operating segment which includes significant expenses by function along with significant non-cash expense items.
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31, |
|
|
2025 |
|
|
2024 |
|
Revenue: |
|
|
|
|
|
Collaboration and license revenue |
$ |
2,171 |
|
|
$ |
566 |
|
Operating expenses: |
|
|
|
|
|
Research and development: |
|
|
|
|
|
Laboratory supplies, research materials and studies |
|
9,489 |
|
|
|
7,276 |
|
Personnel expenses |
|
8,816 |
|
|
|
7,707 |
|
Facility-related and other |
|
5,548 |
|
|
|
3,901 |
|
Clinical studies |
|
3,695 |
|
|
|
3,833 |
|
Stock-based compensation |
|
1,738 |
|
|
|
1,065 |
|
Depreciation expense |
|
502 |
|
|
|
1,075 |
|
General and administrative: |
|
|
|
|
|
Personnel expenses |
|
3,019 |
|
|
|
2,668 |
|
Legal and professional fees |
|
1,954 |
|
|
|
1,668 |
|
Facility-related and other |
|
1,808 |
|
|
|
1,647 |
|
Stock-based compensation |
|
1,676 |
|
|
|
919 |
|
Depreciation Expense |
|
176 |
|
|
|
180 |
|
Loss from operations |
|
(36,250 |
) |
|
|
(31,373 |
) |
Other (expense) income: |
|
|
|
|
|
Interest and other income, net |
|
2,802 |
|
|
|
2,190 |
|
Interest expense |
|
(679 |
) |
|
|
(959 |
) |
Net loss |
$ |
(34,127 |
) |
|
$ |
(30,142 |
) |
|